Search PubMed⌕ Search

Biomedical subjects

P N Vlasov

Publications and source records attributed to P N Vlasov.

10 recordsLinked to original sources
PubMed2006

[The results of the two-year experience of using keppra in therapy of adult patients with epilepsy].

Keppra (levetiracetam) was used as a part of the complex therapy in 87 patients with partial epilepsy and in 17 patients with adult idiopathic generalized epilepsy. Most of the cases were pharmacoresistant. Remission was observed in 25.3% of patients for the period over 12 months. Therapeutic efficacy by a decrease of seizures frequency by 75% and more has been reached in 12.6% of cases; by 50% and more--in 43.7%. The absence of drug effect and insufficient efficacy were detected only in 18.4% of cases. The therapeutic effect was stable and did not decrease after 12 and 24 months. The drug was well tolerated and was withdrawn in 5 cases (4.8%) because of side effects. The results obtained hold promise for using keppra in epileptology, in particular in treatment of pharmacoresistant epilepsy.

Adult↗
PubMed2005

[Efficacy of keppra in combined therapy in pharmacoresistant adult epilepsy patients].

There were analyzed efficacy of keppra (Levetiracetam) in combined therapy in 31 patients with pharmacoresistant partial epilepsy and in 2 cases with idiopathic generalized epilepsy. During the 4 months 48.4% experienced at least a 50% reduction in the frequency of partial-oncet seizures, 12.9% at least a 75% reduction, and 25.8% demonstrated a seizure free. The combined therapy was ineffective only in 12.9%. The authors emphasize a good tolerability of keppra. There was only one case with side-effect, that demand cancel of Levetiracetam. The results obtained reveal effectiveness of keppra using in epileptology, in particular, in pharmacoresistant epilepsy.

Adult↗
PubMed2003

[Experience in combined topiramate therapy of drug-resistant epilepsy].

Efficacy of topiramate usage in combined therapy of 35 patients (25 adults and 10 children) with therapy resistant epilepsy was analyzed. In 11.4% of the cases, medication remission for a period of up to 3 months has been achieved. Therapeutic efficacy, with reducing the number of fits by half was achieved in 40% of the cases. In children topiramate therapy was less beneficial. The authors emphasize a good tolerability of topiramate, along with a first ever described side-effect, emerging as a spot pigmentation. The results obtained reveal effectiveness of topiramate using in epileptology, in particular, in drug-resistant epilepsy.

Adolescent↗
PubMed2002

[Pharmacokinetic aspects of carbamazepine and valproic acid using in reproductive-age women with epilepsy].

Dynamics of carbamazepine and valproic acid concentrations in the middle of follicular and lutein menstrual cycle phases has been studied in women with epilepsy, aged 21-30 years. Nineteen patients were treated with valproic acid (Depakine 900-2000 mg/day), 35--with carbamazepine (500-1200 mg/day). All the patients have been treated during at least 6 months, the remission being observed during the last 3 months. Control group consists of 17 healthy age-matched women with no positive familial history of nervous and endocrine diseases. Carbamazepine and valproic acid concentrations were measured in blood serum using high-performance liquid chromatography. Blood for analysis was donated on an empty stomach in the morning before the next dose (i.e. at the lowest concentration) and two hours after the drug taking. Mean carbamazepine concentrations (4-12 mcg/ml) in the women with epilepsy were adequate when the day dose was more than 10 mg/kg. Carbamazepine concentrations during lutein phase were significantly lower (p < 0.03), comparing to those in the follicular phase. However, in the lutein phase, progesterone, which concentration was ten times higher is follicular one, has an additional effect, acting as anticonvulsive agent. Valproic acid concentrations do not significantly differ in the lutein and follicular phases that allows Depakine using in catamenial epilepsy. Practitioners are not recommended to overestimate the anti-epileptic drug (AED) concentration monitoring because the usage of the lower AED individual therapeutic dose, not achieving even the mean therapeutic drug concentrations, is acceptable. This seems to be of extremely importance for women with potential maternal role function.

Adult↗
PubMed2001

[The pharmacological and hormonal effects of carbamazepine and valproic acid in the treatment of reproductive age women with epilepsy].

Dynamics of steroid hormone (extradiol-17 beta, progesterone, total testosterone and cortisol) concentrations in the middle of follicular and lutein menstrual cycle phases has been studied in women with epilepsy aged 21-30 years. Nineteen patients were treated with valproic acid (depakine--900-2000 mg/day), 35--with carbamazepine (500-1200 mg/day). All the patients have been treated during at least 6 months, paroxysms being not registered during the last 3 months before blood analysis. Control group consisted of 17 healthy age-matched women with no positive familial history of nervous and endocrine diseases. Comparing to the control, the affected groups revealed a significantly lower estradiol level (p < 0.003) during the follicular phase and higher cortisol concentrations during both the follicular and the lutein phases (p < 0.05). Regardless of menstrual cycle phases, the differences in progesterone and total testosterone concentrations have not been found between subgroups treated by carbamazepine and depakine. The same hormonal deviations detected after using both carbamazepine and Depakine in the homogenous subgroups of the patients imply, to a certain extent, a common character of pathogenetic mechanisms for steroid hormone pattern development in women with epilepsy. Carbamazepine and depakine treatment during at least 6 months does not predispose to ovary polycystosis syndrome. The results support a multifactor character of hormonal deviations in epilepsy and do not show the medication factor as a major one.

Adult↗
PubMed1999

[Depakin 300 and Depakin-chrono in the therapy of epilepsy].

The results of administration of Depakin 300 and Depakin-chrono during 4-year period were analysed in 137 patients aged 14-36 years with idiopathic generalized, cryptogenic, symptomatic partial and nonclassified epilepsy. Depakin was prescribed as basic medicine in idiopathic generalized epilepsy, while in partial and nonclassified epilepsy this drug was more frequently administered in combination with some other anticonvulsants. Early administration of Depakin was highly effective: a remission was observed in 91.2% of the patients during a year. During 3 years a remission was observed in 75.4%, frequency of the fits decreased more than by 50%--in 14.1% of the cases, no response was found in 10.5% of the patients (in cases of gross structural changes of the brain, inefficiency of the preceding therapy during 5 years). Frequency of side-effects was 1.7-12.3%. Indications to treatment are discussed: in addition to generally accepted recommendations (absence, myoclonic primary generalized, tonic-clonic forms of epilepsy, of reading, photosensitive epilepsy), application of Depakin is also recommended in nonclassified epilepsy with generalized epileptic EEG-patterns as well as a drug of choice in all cases of nonclassified fits. Depakin is also quite efficient as an additional drug in cases of partial epilepsy resistant to treatment.

Adolescent↗
PubMed1997

[Photosensitive epilepsy].

Photosensitive epilepsy (PE) is the most frequent form of reflex epilepsy. Authors picked out two PE forms based on the analysis of the 16 own observations. The first form is PE with environmental factors of the process' provocation, which is characterised by genuine character of disease, pre- and pubertal period of its beginning, considerable prevalence of males among the patients, rare generalized tonic and clonic fits and favorable prognosis. The second form of PE is significantly rarer PE form -with self-induction of the fits. It is characterized by the beginning of the disease in preschool period, even sex distribution, quite frequent evaluated organic damages of brain, nonconvulsive fits, non-efficiency of antiepileptic drugs. The mechanisms of pathogenesis and the ways of fits' prophylaxis were discussed.

Adolescent↗
PubMed1994

[The role of the female sex hormones in the pathogenesis of catamenial epileptic seizures].

The paper presents the results of evaluation of gonadotropins and female steroids concentrations in 46 female epileptics on catamenia day 1, in the middle of follicular and lutein phases. The control consisted of 7 healthy females of the same age with favourable heredity and free of neuroendocrine diseases. Two groups of patients were distinguished: females with catamenial epileptic seizures and those with catamenia-independent seizures. It is shown that changes in the concentrations of female steroid sex hormones were unidirectional in both the groups with a tendency to deficient luteal phase and relative hyperestrogenemia in all the cycle phases. The involvement of insufficient activation produced by brain stem formation reticularis in pathogenesis of catamenial epilepsy in suggested. A pathogenetic approach to epilepsy treatment in females when hormonal status is considered and psychostimulators are used is proposed.

Adolescent↗
PubMed1993

[The clinical and electrophysiological aspects of catamenial epilepsy].

Clinical and electrophysiological methods were used to examine 25 women of fertile age, suffering from catamenial epilepsy (CE), 18 patients with a well-defined relationship between disease exacerbation and menstruation, and 7 patients without the given relationship. Electroencephalography followed by compression spectral analysis was carried out over time, namely on days, 1, 7 and 21 of the menstrual cycle. Significant differences were found between the groups as regards the clinical and electrophysiological characteristics. This enabled the authors to regard the group comprising 18 patients with a rigid relationship between epilepsy exacerbations and the menstrual period as having an isolated CE syndrome.

Adolescent↗